Strekin Announces Completion of Patient Recruitment in Phase 3 Clinical Study of Hearing Loss Drug
BASEL, SWITZERLAND — Strekin AG, a biopharmaceutical company focused on treatments for hearing loss, announced that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3 clinical trial of the investigational drug STR001 in patients following a Sudden Sensorineural Hearing Loss (SSNHL) event. RESTORE is evaluating the ability of…
Read MoreStrekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss
BASEL, SWITZERLAND — Strekin AG, a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totaling CHF 2.82 Million (~$2.86M USD) from private investors. According to the announcement, the funds will enable Strekin to conclude its ongoing Phase 3 clinical trial of STR001 in Sudden Sensorineural Hearing Loss,…
Read More
Swiss Biotech, Strekin, Secures Funding for Second Clinical Trial of Hearing Loss Drug
BASEL, SWITZERLAND — Strekin AG announced this week that it had successfully closed a Seed C financing round totaling CHF10 million (approximately $10.3 USD) from private investors. The latest financing round allows the company to conduct a second clinical trial of its leading drug candidate, STR001, as a potential new treatment for sudden sensorineural hearing…
Read More